

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods

Blairon, Laurent; Wilmet, Alain; Beukinga, Ingrid; Tré-Hardy, Marie

Published in:
Journal of Clinical Virology

DOI:
[10.1016/j.jcv.2020.104472](https://doi.org/10.1016/j.jcv.2020.104472)

Publication date:
2020

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for pulished version (HARVARD):
Blairon, L, Wilmet, A, Beukinga, I & Tré-Hardy, M 2020, 'Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital', *Journal of Clinical Virology*, vol. 129, 104472. <https://doi.org/10.1016/j.jcv.2020.104472>


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Short communication

Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital

Laurent Blairon^a, Alain Wilmet^a, Ingrid Beukinga^a, Marie Tré-Hardy^{a,b,c,*}^a Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium^b Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium^c Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium

ARTICLE INFO

Keywords:

COVID-19
SARS-CoV-2
Point-of-care
Rapid diagnosis
Antigen testing
qRT-PCR

ABSTRACT

Background: The COVID-19 Ag (Antigen) Respi-Strip assay is a new immunochromatographic diagnostic tool recently available for antigenic diagnosis of SARS-CoV-2. The proposed sensitivity is not higher than 60 %, but its high specificity allows both quick decisions for the management of patients and confirmation by molecular diagnosis for only negative tests. However, from the first tests performed, we suspected that the sensitivity observed with routine use was much lower than that announced by the manufacturer.

Materials and methods: Over a period of one month, we compared the negative results obtained with the COVID-19 Ag Respi-Strip kit with those obtained from qRT-PCR performed in a laboratory qualified for the molecular diagnosis of SARS-CoV-2. All samples tested were naso-pharyngeal smears from UTM-RT medium.

Results: Of 774 patients tested, 714 negative samples were sent for confirmation, and 159 were found to be positive by qRT-PCR. The median positive percentage agreement was 23.9 % (95 % CI: 14.2 %–38.2 %). The Cohen's kappa score was 0.35.

Conclusion: Using this immunochromatographic assay as a triage test did not significantly reduce the number of samples outsourced for COVID-19 confirmation by qRT-PCR. In addition, even if the turn-around time is short, the assay is completely manual, which is not suitable for large volumes of routine samples. The sensitivity of this rapid test is poor, and improvements are needed to enhance its performance.

1. Introduction

Since the launch of the COVID-19 Ag Respi-Strip assay (Coris Bioconcept, Gembloux, Belgium) upon completion of a validation study under the National Competent Authority supervision, we enthusiastically implemented the company's proposed algorithm allowing the integration of this rapid test in the management of patients suspected of COVID-19. This decision was based on the significant specificity reported (99.5 %) that allows quick decisions regarding the management of patients. Negative results require additional examinations by medical imaging and molecular detection by qRT-PCR.

We read with great interest the early April WHO advice on the use of point-of-care immunodiagnostic tests for COVID-19 [1] as well as the article recently published on the test validation [2] and wanted to evaluate our current way of working.

2. Materials and methods

This prospective study was conducted over a 1-month period between April 5, 2020, and May 4, 2020, at a single 550-bed hospital site. The beginning of this period corresponded to the epidemic peak of COVID-19 in Belgium. Nasopharyngeal samples for the diagnosis of COVID-19 were taken from UTM-RT swabs (Copan spa, Brescia, IT) and sent to the laboratory. The antigenic assessment was performed using the COVID-19 Ag Respi-Strip kit according to the manufacturer's instructions. After antigenic testing was performed, the molecular assessment of SARS-CoV-2 was outsourced to a university centre where it was carried out by qRT-PCR using E-gene SARS-CoV-2 primers/probes.

3. Results

A rapid on-site verification of the performance of the COVID-19 Ag Respi-Strip kit was carried out on 56 samples; it showed a sensitivity of 30 % (95 % CI: 16.7 %–47.9 %) a specificity of 100 %, and a positive

* Corresponding author at: Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Belgium.

E-mail address: marie.tre-hardy@ulb.ac.be (M. Tré-Hardy).

<https://doi.org/10.1016/j.jcv.2020.104472>

Received 17 May 2020; Received in revised form 22 May 2020; Accepted 25 May 2020

1386-6532/ © 2020 Elsevier B.V. All rights reserved.




Fig. 1. Evolution of the number of positive and negative PCRs among samples sent for confirmation of negative antigenic testing and the percentage of positive PCRs (solid line) and antigenic testing (dashed line) during the 4 weeks of observation.

predictive value of 100 %, validating the decision not to confirm a positive result. During the investigation period, 912 tests were performed. Some patients were tested more than once for follow-up according to the handling clinician's decision. After removing duplicates, 776 patients remained for evaluation. Two tests were removed from the statistical analysis (one non-conform and one invalid). Sixty (60) out of 774 antigenic strips were positive. Fig. 1 shows the evolution of positive and negative molecular confirmations over the weeks as well as the percentage of positive molecular and antigenic tests. The total number of positive PCR samples was 159. The positive percentage agreement during the 4 weeks ranged from 14.3 % to 34.7 % with a median of 23.9 % (95 % CI: 14.2 %–38.2 %). The Cohen's kappa score was 0.35.

4. Discussion

Under routine conditions, the sensitivity of the antigen detection of SARS-CoV-2 with the immunochromatographic COVID-19 Ag Respi-Strip kit was significantly lower than that announced by the manufacturer or reported by Vandenberg [2], although we limited ourselves to using qRT-PCR as the comparison method. In our series, we observed a median sensitivity of 23.9 %. Moreover, compared with the expected performance, the poor observed sensitivity gave rise to 80 % more false negative samples and 2.2 times fewer positive samples answered on site.

Some authors reported a sensitivity of similar molecular methods close to 70 % [3]. To obtain a better understanding of the actual sensitivity, we used the patient database constructed for a serological evaluation for which approval was obtained from our Ethics Committee [4]. When combining molecular diagnosis, chest CT scans and suggestive clinical patterns of COVID-19, we observed that PCR was positive in only 199 patients among the 236 patients (76.2 %) with suggestive symptoms of COVID-19 or a positive chest CT. These results are in line with the previously published false negative rate of approximately 20 % for qRT-PCR [5–7].

As mentioned in the WHO advice [1], the performances of antigenic tests depend on several factors, such as the time from onset of illness, the specimen viral content, and other preanalytical and analytical considerations, as has been previously reported for other respiratory viruses. The WHO estimates that at least half of COVID-19-infected patients might be missed by such tests and therefore does not currently recommend their use. Vandenberg calculated their performance based on a threshold cycle (Ct) below 22 [2]. In the meantime, a notice from the manufacturer signalled that some hospitals observed negative results with a Ct of 13.45 or positive results with a Ct higher than 33, underlining the unclear relationship between protein and RNA

detection. The main limitation of our investigation was our inability to match our results against the Ct of the molecular analyses since these were outsourced. We also focused on the sensitivity of the test. However, specificity did not appear to be a priority, given that the high prevalence of disease amplifies positive predictive value of the test when it is prescribed for patients in a COVID-19-compatible clinic.

5. Conclusion

Our routine results demonstrate that the concordance between antigenic and molecular testing is fair regarding the kappa score [8] and that this rapid assay does not reduce costs per patient. A thorough validation in appropriate populations and settings should have been performed by the manufacturer before a large-scale implementation.

Funding

There were no funding resources to declare for this study.

CRediT authorship contribution statement

Laurent Blairon: Conceptualization, Methodology, Data curation, Formal analysis, Validation, Writing - original draft. **Alain Wilmet:** Conceptualization, Methodology, Data curation, Formal analysis, Validation, Writing - review & editing. **Ingrid Beukinga:** Conceptualization, Methodology, Data curation, Formal analysis, Validation, Writing - review & editing. **Marie Tré-Hardy:** Conceptualization, Methodology, Data curation, Formal analysis, Validation, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank all the members of the clinical laboratory staff for their technical assistance.

References

- [1] World Health Organisation (Ed.), Advice on the Use of Point-of-Care Immunodiagnostic Tests for COVID-19, Scientific brief, (2020), 2020, <https://apps.who.int/iris/handle/10665/331713>.
- [2] O. Vandenberg, Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context, Infectious Diseases (except HIV/AIDS), (2020), <https://doi.org/10.1101/2020.04.24.20077776>.
- [3] Y. Fang, H. Zhang, J. Xie, M. Lin, L. Ying, P. Pang, W. Ji, Sensitivity of chest CT for COVID-19: comparison to RT-PCR, Radiology (2020) 200432, <https://doi.org/10.1148/radiol.2020200432>.
- [4] M. Tré-Hardy, A. Wilmet, I. Beukinga, J.M. Dogné, J. Douxfils, L. Blairon, Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody, Clin. Chem. Lab. Med. (2020), <https://doi.org/10.1515/cclm-2020-0594> [published online ahead of print, 2020 May 25].
- [5] W. Zhang, R.-H. Du, B. Li, X.-S. Zheng, X.-L. Yang, B. Hu, Y.-Y. Wang, G.-F. Xiao, B. Yan, Z.-L. Shi, P. Zhou, Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes, Emerg. Microbes Infect. 9 (2020) 386–389, <https://doi.org/10.1080/22221751.2020.1729071>.
- [6] X. Xie, Z. Zhong, W. Zhao, C. Zheng, F. Wang, J. Liu, Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing, Radiology (2020) 200343, <https://doi.org/10.1148/radiol.2020200343>.
- [7] T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, L. Xia, Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases, Radiology (2020) 200642, <https://doi.org/10.1148/radiol.20200642>.
- [8] P.F. Watson, A. Petrie, Method agreement analysis: a review of correct methodology, Theriogenology 73 (2010) 1167–1179, <https://doi.org/10.1016/j.theriogenology.2010.01.003>.